The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa ...

Another study of more than 55,000 long-term care residents in Ontario, Canada, showed a second booster dose of Moderna’s shot increased vaccine effectiveness against infection with omicron ...

The FDA also authorized a single booster dose of the Moderna COVID-19 Vaccine for individuals who have completed a primary vaccination with other authorized or approved COVID-19 vaccines.

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...

The second arm of Moderna’s omicron booster trial has gotten underway with a first patient dosed in the phase 2 study testing a variant-specific vaccine against COVID-19. The trial is combining ...

Moderna Inc. stock rose more than 1% in the extended session Wednesday after the biotechnology company said that a single-dose booster COVID-19 vaccine worked against the novel coronavirus ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The updated (bivalent) Moderna booster can be given to anyone ages 6 months or older at least 2 months after 2nd primary series dose or last booster. Johnson & Johnson vaccine.

After you’ve got the two jabs required for the primary series of the mRNA vaccine, people 6 months or older are eligible for a booster shot 2 months after the last dose. Moderna.

Crude incidence rates of CSU following a booster dose in the two cohorts was 1.9-2.1 per 100,000 doses of Pfizer's vaccine and 30.8-43.9 per 100,000 doses of Moderna's product, according to their ...